Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis

Journal of Bone and Mineral Research

Volumn 19, Issue 10, 2004, Pages 1712-1721

  Nyambo, Rachel ^a   Cross, Neil ^a   Lippitt, Jenny ^a   Holen, Ingunn ^a,b   Bryden, Gorden ^a,b   Hamdy, Freddie C ^a,b   Eaton, Colby L ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Apoptosis; Human bone marrow stromal cells; Osteoprotegerin; Prostate cancer; sRANKL; TRAIL

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; CELL RECEPTOR; GLYCOPROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; BONE BIOPSY; BONE MARROW CELL; BONE METASTASIS; CANCER CELL; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROSTATE CANCER; STROMA CELL; WESTERN BLOTTING; BONE TUMOR; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE MARROW CELLS; BONE NEOPLASMS; CARRIER PROTEINS; CELLS, CULTURED; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13444294592     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040703     Document Type: Article

References (28)

1. Hsing AW, Tsao L, Devesa SS 2000 International trends in patterns of prostate cancer incidence and mortality. Int J Cancer 85:60-67.
2. Mundy GR 1997 Mechanisms of bone metastasis. Cancer 80(Suppl):1547-1554.
3. Koeneman KS, Yeung F, Chung LWK 1999 Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone microenvironment. Prostate 39:246-261.
4. Goltzman D 1997 Mechanisms of the development of osteoblastic metastasis. Cancer 80(Suppl):1573-1580.
5. Chackal-Roy M, Niemeyer C, Moore M, Zetter BR 1989 Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 84:43-50.
6. Okamoto M, Lee C, Oyasu R 1997 Interleukin 6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141-146.
7. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC 2000 Interleukin 6 induces the prostate cancer cell growth accompanied by activation of Stat3 signalling pathway. Prostate 42:239-242.
8. Chung TDK, Yu JJ, Kong TA, Spiotto MT, Lin JM 2000 Interleukin 6 activates phophatidylinositol-3 kinase, which inhibits apoptosis in human cancer cell lines. Prostate 42:1-7.
9. Kostenuik PJ, Singh G, Orr FW 1997 Transforming growth factor β upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type 1 collagen. Clin Exp Metastasis 15:41-52.
10. Nakamoto T, Chang C, Li A, Chodak GW 1992 Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 52:571-577.
11. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC 1999 Elevated levels of circulating IL-6 and TGF/β1 in patients with metastatic prostate carcinoma. J Urol 161:182-187.
12. Simmonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliot R, Colombero A, Tan HL, Trail G, Sullivan J, Davey E, Bucay N, Renshaw-Gregg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ 1997 Osteoprotegrin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
13. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morianga T, Higashio K 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142.
14. Khosla S 2001 Minireview: The OPG/RANKL/RANK system. Endocrinology 142:5050-5055.
15. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E 2001 Serum osteoprotegrin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7:2977-2983.
16. Jung K, Lein M, von Hosslin K, Brux B, Schnorr D, Loening SA, Sinha P 2001 Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin Chem 47:2061-2063.
17. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenburg M, Lee JC, Young PR 1998 Osteoprotegrin is a receptor for cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367.
18. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A 1996 Induction of apoptosis by Apo-2 ligand, a new member of the tumour necrosis factor cytokine family. J Biol Chem 271:12687-12690.
19. Gura T 1997 How TRAIL kills cancer cells but not normal cells. Science 277:768.
20. Velthuis JHL, Rouschop KMA, de Bont HJGM, Mulder GJ, Nagelkerke JF 2002 Distinct intracellular signalling in TRAIL and CD95L-mediated apoptosis. J Biol Chem 277:24631-24637.
21. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM 1997 An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818.
22. Sheridan P, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramarkrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A 1997 Control of TRAIL induced apoptosis by a family of signalling and decoy receptors. Science 277:818-821.
23. Holen I, Croucher PI, Hamdy FC, Eaton CL 2002 Osteoprotegrin is a survival factor for human prostate cancer cells. Cancer Res 62:1619-1623.
24. Klinger HC, Bretland AJ, Reid SV, Chapple CR, Eaton CL 1999 Regulation of prostatic stromal growth and function by transforming growth factor beta. Prostate 41:110-120.
25. Ibaraki K, Whitson S, Termine JD, Young MF 1992 Bone matrix mRNA expression in differentiating foetal bovine osteoblasts. J Bone Miner Res 7:743-754.
26. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K 2002 Critical role for tumour necrosis factor-related apoptosis inducing ligand in immune surveillance against tumour development. J Exp Med 195:161-169.
27. Yu R, Mandelkar S, Rueben S, Ni J, Kong AN 2000 Tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 60:2384-2389.
28. Zhang J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET 2001 Osteoprotegerin inhibits prostate cancer induced osteoclastogenesis and prevents prostate tumour growth in the bone. J Clin Invest 107:1235-1244.